Abstract 1481P
Background
ICIs have transformed the treatment of advanced NSCLC patients, no real-world data are available about the immune-related adverse events (irAEs). This retrospective study aimed to assess the safety and effectiveness of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer (NSCLC) and to analyze the association between singular irAEs and effectiveness.
Methods
This was a retrospective study of the clinical data of patients with NSCLC treated with PD-1/PD-L1 inhibitors as 1a or 2a lines from Marzo 2015 to Marzo 2022 at Hospital Universitario Regional de Málaga. We evaluated association of irAE with efficacy, response and overall survival. Kaplan-Meier and Cox proportional hazard analyses were performed.
Results
A total of 510 patients were included in this analysis. Any grade IrAEs were seen in 307 (60%) patients. Of these (Table), 135 (43,9%) patients had grade 1 toxicities, most commonly cutaneous (96), colitis (54), rheumatologic (46) and hepatitis (42). 112 (36,4%) patients had grade 2 toxicities pneumonitis (47), cutaneous (29), colitis (28). 53 (17,2%) patients had grade 3 toxicities: hepatitis (15), pneumonitis (13), cutaneous (10). 8 (2,6 %) patients had grade 4 toxicities hepatitis (5), pneumonitis (2), DRESS syndrome (1). For patients assessed for efficacy, objective response rate (ORR) to ICI was higher in patients with irAEs [46% vs 14%] p=0,001. In fact, the presence of any irAEs had a significantly improved median OS compared to those without irAEs (19,3 months vs 6,5 p = 0.0001) (Median OS in G1-2 20 months and G 3-4 16,2 months had significally higher OS vs non irAEs 6,1 months; p=0,0001). Singular toxicities that predict greater OS >30 months were (Hepatitis G4, endocrine G1 and cutaneous G2); point out toxicities with deleterious effects (colitis G3 and pneumonitis G4). Multivariable analysis demonstrated that the development of any irAEs was related to a significantly improved OS (HR 0.47, 95% 0.26-0.68, p = 0.0001).
Table: 1481P
Summary of singular toxicities and OS (overall survival) in months
IrAEsN 307 | Cutaneous 135 OS | Pneumo92 OS | Colitis89 OS | Hepatitis79 OS | Rheuma76 OS | Endocrine61 OS | Renal40 OS |
G1 135 | 96 28.2 | 29 18.3 | 54 21.4 | 42 18.7 | 46 28.8 | 40 37.8 | 19 21.4 |
G2 112 | 29 31.1 | 47 13.8 | 28 21.4 | 17 19 | 28 20.1 | 18 28.8 | 14 28.2 |
G3 53 | 10 13.4 | 13 15.3 | 7 7.2 | 15 20.6 | 2 3.8 | 3 - | 7 7.2 |
G4 8 | - | 3 1.9 | - | 5 40.6 | - | - | - |
Non N Ir 203 | 375 9.0 p=0.0001 | 418 11.4 p=0.54 | 421 11.2 p=0.018 | 431 11.6 p=0.146 | 434 11.1 p=0.001 | 449 11.1 p=0.001 | 470 12.6 p=0.05 |
Conclusions
This study confirms the feasibility and the safety of ICIs in a large, real-world cohort of patients with NSCLC. The development of irAEs in NSCLC patients treated with immunotherapy may predict better treatment efficacy and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21